The indications for use of programed cell death receptor (PD-1) inhibitors to treat cancer continues to expand rapidly. Treatment with PD-1 inhibitors has been associated with numerous immune-mediated mucocutaneous side effects. Here, we report 2 cases of severe mucositis caused by the PD-1 inhibitor pembrolizumab and review the defining features of similar cases. Recognition of mucocutaneous toxicities of PD-1 inhibitors is increasingly important as their use continues to expand. A stepwise approach to diagnosis and management is also reviewed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.joms.2020.11.023 | DOI Listing |
Publication Analysis
Top Keywords
pd-1 inhibitors
12
severe mucositis
8
continues expand
8
mucositis secondary
4
secondary pembrolizumab
4
pembrolizumab reports
4
reports cases
4
cases review
4
review literature
4
literature algorithm
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!